Substance P is associated with the development of obesity, chronic inflammation and type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 119, Issue 3, 2011, Pages 177-181

  Fu, J ^a   Liu, B ^a   Liu, P ^b   Liu, L ^d   Li, G ^b   Wu, B ^c   Liu, X ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

C reactive protein; diabetes; HOMA IR; interleukin 6; obesity; substance P

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; SUBSTANCE P;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; SUBSTANCE P; TRIGLYCERIDES; URIC ACID;

EID: 79952370968     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1261965     Document Type: Article

References (31)

1. Alvaro G, Di Fabio R. Neurokinin 1 receptor antagonists - current prospects. Curr Opin Drug Discov Devel 2007 10 5 613-621 (Pubitemid 47367776)
2. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997 20 7 1183-1197
3. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science 2005 307 5717 1909-1914 (Pubitemid 40404693)
4. Burdo JR, Chen Q, Calcutt NA, etal. The pathological interaction between diabetes and presymptomatic Alzheimer's disease. Neurobiol Aging 2009 30 12 1910-1917
5. Chang MN, Leeman SE. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as Substance P. J Biol Chem 1970 245 18 4784-4790
6. Cummings J, MacLellan A, Langdon SP, etal. Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-performance liquid chromatography. J Pharm Biomed Anal 1994 12 6 811-819
7. de Almeida BB, Mathias MG, Portari GV, etal. Chronic acetonemia alters liver oxidative balance and lipid content in rats. A model of NASH? Exp Clin Endocrinol Diabetes 2010 118 1 61-63
8. Dietrich MO, Horvath TL. Feeding signals and brain circuitry. Eur J Neurosci 2009 30 9 1688-1696
9. Fleischman A, Shoelson SE, Bernier R, etal. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008 31 2 289-294 (Pubitemid 351213338)
10. Gustafson B. Adipose Tissue, Inflammation and Atherosclerosis. J Atheroscler Thromb 2010 Feb 3 [Epub ahead of print]
11. Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol 2001 33 6 555-576 (Pubitemid 32510811)
12. International Diabetes Federation - Western Pacific Region. Asian-Pacific Type 2 diabetes Policy Group. Type 2 Diabetes: Practical Targets and Treatments, 4th Edition 2005 Available at: http://www.idf.org/webdata/docs/T2D- practical-tt.pdf (Last accessed: April 13, 2010)
13. Karagiannides I, Kokkotou E, Tansky M, etal. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci U S A 2006 103 13 5207-5212
14. Karagiannides I, Torres D, Tseng YH, etal. Substance P as a novel anti-obesity target. Gastroenterology 2008 134 3 747-755
15. Koon HW, Zhao D, Zhan Y, etal. Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc Natl Acad Sci U S A 2007 104 6 2013-2018 (Pubitemid 46239895)
16. Joslin G, Krause JE, Hershey AD, etal. Amyloid-beta peptide, substance P, and bombesin bind to the serpin-enzyme complex receptor. J Biol Chem 1991 266 32 21897-21902 (Pubitemid 121000265)
17. Mather KJ, Funahashi T, Matsuzawa Y, etal. Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008 57 4 980-986
18. Miklossy J, Qing H, Radenovic A, etal. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 2008. Oct 23 [Epub ahead of print]
19. Percik R, Stumvoll M. Obesity and cancer. Exp Clin Endocrinol Diabetes 2009 117 10 563-566
20. Pieri M, Amadoro G, Carunchio I, etal. SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels. Neuropharmacology 2010 58 1 268-276
21. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 1997 31 6 537-563 (Pubitemid 28037471)
22. Ribeiro-da-Silva A, Hokfelt T. Neuroanatomical localisation of Substance P in the CNS and sensory neurons. Neuropeptides 2000 34 5 256-271
23. Samy N, Hashim M, Sayed M, etal. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 2009 26 4 163-170
24. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010 87 1 4-14
25. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007 132 6 2169-2180 (Pubitemid 46693756)
26. Takenouchi T, Munekata E. Trophic effects of substance P and beta-amyloid peptide on dibutyryl cyclic AMP-differentiated human leukemic (HL-60) cells. Life Sci 1995 56 26 PL479-PL484
27. Thorand B, Kolb H, Baumert J, etal. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes 2005 54 10 2932-2938 (Pubitemid 41401089)
28. Tian F, Luo R, Zhao Z, etal. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 2010 118 4 258-265
29. Yudkin JS, Eringa E, Stehouwer CD. Vasocrine signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005 365 9473 1817-1820 (Pubitemid 40744663)
30. World Health Organization. Obesity and overweight. 2003 Available at: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ (Last accessed: April 12, 2010)
31. World Health Organization - Western Pacific Region. The Asia-Pacific perspective: Redefining obesity and its treatment. 2000 Available at: http://www.wpro.who.int/internet/resources.ashx/NUT/Redefining+obesity.pdf (Last accessed: April 26, 2010)